<!DOCTYPE html>
<html>
<head>
    <title>Neuroblastoma Electronic Health Records Open Data Lake</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

    <link href="//netdna.bootstrapcdn.com/twitter-bootstrap/2.3.2/css/bootstrap-combined.min.css" rel="stylesheet">
  
</head>
  <body class="container">

<figure>
    <a href="https://davidechicco.github.io/neuroblastoma_EHRs_data_lake/index.html"><img src="./banner2.png" width="1200" align="center"/></a>
</figure>  
  

<table border="0" class="table" style="100%" style="white-space:nowrap;">
    <tr>
        <td width="300" style="text-align:center"><a href="index.html"> <font size="+2">home</font></a></td>
        <td width="300" style="text-align:center"><a href="datasets.html"> <font size="+2">datasets</font></a></td>
        <td width="300" style="text-align:center"><a href="contacts_and_credits.html"> <font size="+2">contacts and credits</font></a></td>
        <tr>
</table>

<!-- end of the header that is the same for each webpage -->
  
  
<h1>Datasets</h1>

At the moment, five datasets are present here, all available under the CC BY-NC 4.0 license: dataBB2013, dataCK2018, dataEV2013, dataYBC2019, and dataYM2018.
<hr>

<!-- dataBB2013 dataBB2013 dataBB2013 dataBB2013 dataBB2013 dataBB2013 dataBB2013 dataBB2013 dataBB2013 dataBB2013 dataBB2013 dataBB2013  -->

<h3>dataBB2013</h3>
Quantitative characteristics: 121 patients, 13 features, released in 2013. License: CC BY-NC 4.0. File type: .xls
</br>
<a href="https://doi.org/10.1371/journal.pone.0063253" target="_blank" rel="noopener noreferrer">Original dataset article</a>.
</br>
</p>

<table class="table table-bordered table-hover table-condensed">
<thead><tr><th title="Field #1">feature</th>
<th title="Field #2">meaning</th>
<th title="Field #3">type</th>
<th title="Field #4">values</th>
</tr></thead>
<tbody><tr>
<td>Age at diagnosis</td>
<td>age at diagnosis</td>
<td>months</td>
<td>2, ..., 196</td>
</tr>
<tr>
<td>Ferritin</td>
<td>ferritin serum level</td>
<td>ng/ml</td>
<td>-99, 19, ..., 2250</td>
</tr>
<tr>
<td>Histology</td>
<td>Histological category </td>
<td>categorical</td>
<td>NS, NB, GNB</td>
</tr>
<tr>
<td>INRG Risk classification</td>
<td>risk group: HR: high risk</td>
<td>categorical (only one value)</td>
<td>1</td>
</tr>
<tr>
<td>INSS Stage</td>
<td>Stage of the tumor (only stage 4 patients)</td>
<td>categorical (only one value)</td>
<td>1</td>
</tr>
<tr>
<td>Methylation PCDHB cluster (%)</td>
<td>methylation of 17 genes of the Protocadherin B cluster</td>
<td>percentage</td>
<td>29.44, ..., 88.93</td>
</tr>
<tr>
<td>Methylation SFN (%)</td>
<td>methylation of the SFN gene</td>
<td>percentage</td>
<td>36.6, ..., 99</td>
</tr>
<tr>
<td>MYCN amplification</td>
<td>Status of nMYC oncogene: 0, amplified, 1, unamplified;</td>
<td>binary</td>
<td>0, 1</td>
</tr>
<tr>
<td>OS</td>
<td>overall survival</td>
<td>months</td>
<td>0.27, ..., 164.47</td>
</tr>
<tr>
<td>Outcome</td>
<td>Clinical Outcome</td>
<td>categorical</td>
<td>AICR, AWD, AWSD, CR, DOD</td>
</tr>
<tr>
<td>PFS</td>
<td>progression free survival</td>
<td>months</td>
<td>3.7, ...., 74.7, NaN</td>
</tr>
<tr>
<td>Set of patients</td>
<td>Training\Testing division of patients</td>
<td>binary</td>
<td>0, 1</td>
</tr>
</tbody></table>

</br>
</p>



<a href="https://figshare.com/articles/dataset/_Clinical_Potentials_of_Methylator_Phenotype_in_Stage_4_High_Risk_Neuroblastoma_An_Open_Challenge_/705932?file=1065974" target="_blank" rel="noopener noreferrer">
Download the dataBB2013 dataset</a> &nbsp; &nbsp; &nbsp;
<a href="https://figshare.com/articles/dataset/_Clinical_Potentials_of_Methylator_Phenotype_in_Stage_4_High_Risk_Neuroblastoma_An_Open_Challenge_/705932?file=1065974" target="_blank" rel="noopener noreferrer">
<img src="download_button.png" align="centre" width="150">
</a>
</br>
</p>


<hr>

<!-- dataCK2018 dataCK2018 dataCK2018 dataCK2018 dataCK2018 dataCK2018 dataCK2018 dataCK2018 dataCK2018 dataCK2018 dataCK2018 dataCK2018    -->

<h3>dataCK2018</h3>
Quantitative characteristics: 20 patients, 17 features, released in 2018.  License: CC BY-NC 4.0. File type: .xls
</br>
<a href="https://doi.org/10.3345/kjp.2018.61.2.53" target="_blank" rel="noopener noreferrer">Original dataset article</a>.
</br>
</p>


<table class="table table-bordered table-hover table-condensed">
<thead><tr><th title="Field #1">feature</th>
<th title="Field #2">meaning</th>
<th title="Field #3">type</th>
<th title="Field #4">values</th>
</tr></thead>
<tbody><tr>
<td>11q-</td>
<td>presence of chromosomal aberration  at 11q site</td>
<td>boolean</td>
<td>yes, no, -</td>
</tr>
<tr>
<td>171+</td>
<td>presence of chromosomal aberration at 17q site</td>
<td>boolean</td>
<td>yes, no, -</td>
</tr>
<tr>
<td>1p-</td>
<td>presence of chromosomal aberration  at 1p site</td>
<td>boolean</td>
<td>yes, no, -</td>
</tr>
<tr>
<td>age</td>
<td>age</td>
<td>months</td>
<td>0, ..., 10.2</td>
</tr>
<tr>
<td>Ferritin</td>
<td>ferritin levels</td>
<td>ng/mL</td>
<td>15, ..., 1638.6</td>
</tr>
<tr>
<td>LDH</td>
<td>lactic acid dehydrogenase levels</td>
<td>U/L</td>
<td>539, ..., 6200</td>
</tr>
<tr>
<td>Local RTx dose (gy)</td>
<td>dosage of radiation</td>
<td>float</td>
<td>15, 23.4, 25.2, -</td>
</tr>
<tr>
<td>Metastatic sites</td>
<td>site of metastsoization</td>
<td>categorical</td>
<td>BM, Bone, Kidney, liver, LN, lung,</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> </td>
<td>mediastinum, muscle, pleura, skin</td>
</tr>
<tr>
<td>NSE</td>
<td>neuron-specific enolase levels</td>
<td>float</td>
<td>7.3, ..., 947</td>
</tr>
<tr>
<td>Outcome </td>
<td>alive or dead</td>
<td>boolean</td>
<td>NED, EFS</td>
</tr>
<tr>
<td>Outcome_mo</td>
<td>follow-up </td>
<td>monhths</td>
<td>17, ..., 91</td>
</tr>
<tr>
<td>Patients no.</td>
<td>ID</td>
<td>integer</td>
<td>code</td>
</tr>
<tr>
<td>Primary site</td>
<td>tumor primary site</td>
<td>binary</td>
<td>abdomen, mediastinum</td>
</tr>
<tr>
<td>Sex</td>
<td>F/M</td>
<td>binary</td>
<td>M/F</td>
</tr>
<tr>
<td>Tumor response after CT &amp; S</td>
<td>patient response after chemotheraphy and surgey</td>
<td>categorical</td>
<td>CR, MR, PR, VGPR</td>
</tr>
<tr>
<td>Tumor response after DT</td>
<td>patient response after differentiation theraphy (DT)</td>
<td>categorical</td>
<td>CR, MR, PR, VGPR</td>
</tr>
<tr>
<td>Urine VMA</td>
<td>vanillylmandelic acid levels in urine</td>
<td>mg/day</td>
<td>0.5, ..., 53.9</td>
</tr>
</tbody></table>

</br>
</p>


<a href="https://www.e-cep.org/journal/Table.php?xn=kjped-61-53.xml&id=T2-kjped-61-53&mode=export" target="_blank" rel="noopener noreferrer">
Download the dataCK2018 dataset</a> &nbsp; &nbsp; &nbsp;
<a href="https://www.e-cep.org/journal/Table.php?xn=kjped-61-53.xml&id=T2-kjped-61-53&mode=export" target="_blank" rel="noopener noreferrer">
<img src="download_button.png" align="centre" width="150">
</a>
</br>
</p>

<hr>

<!-- dataEV2013 dataEV2013 dataEV2013 dataEV2013 dataEV2013 dataEV2013 dataEV2013 dataEV2013 dataEV2013 dataEV2013 dataEV2013     -->

<h3>dataEV2013</h3>
Quantitative characteristics: 19 patients, 12 features, released in 2013.  License: CC BY-NC 4.0. File type: .xls
</br>
<a href="https://doi.org/10.1371/journal.pone.0053740" target="_blank" rel="noopener noreferrer">Original dataset article</a>.
</br>
</p>

<table class="table table-bordered table-hover table-condensed">
<thead><tr><th title="Field #1">feature</th>
<th title="Field #2">meaning</th>
<th title="Field #3">type</th>
<th title="Field #4">values</th>
</tr></thead>
<tbody><tr>
<td>Age at diagnosis</td>
<td>age</td>
<td>months</td>
<td>9, ..., 108</td>
</tr>
<tr>
<td>Follow-up time</td>
<td>Overall survival</td>
<td>months</td>
<td>1, ..., 132</td>
</tr>
<tr>
<td>ID</td>
<td>ID</td>
<td>integer</td>
<td>code</td>
</tr>
<tr>
<td>Metastases</td>
<td>Presence of metastasis</td>
<td>boolean</td>
<td>yes, no</td>
</tr>
<tr>
<td>Outcome</td>
<td>Clinical outcome</td>
<td>categorical</td>
<td>ADF, AWD, DOD, DOS, DTC</td>
</tr>
<tr>
<td>Pathology</td>
<td>Patological category </td>
<td>categorical</td>
<td>nGNB, pdNB, uNB<br/></td>
</tr>
<tr>
<td>Protocol Treatment</td>
<td>Treatment protocol</td>
<td>categorical</td>
<td>HR-NBL1, INES, LNESG1, N-II-92, NAR-99</td>
</tr>
<tr>
<td>Relapse</td>
<td>relapsed Yes or no</td>
<td>boolean</td>
<td>yes/no</td>
</tr>
<tr>
<td>Sex</td>
<td>M/F</td>
<td>binary</td>
<td>M/F</td>
</tr>
<tr>
<td>Stage</td>
<td>Stage of the tumor</td>
<td>categorical</td>
<td>1, 2, 3, 4</td>
</tr>
<tr>
<td>Time to first relapse</td>
<td>time to first relapse</td>
<td>months</td>
<td>4, ..., 28</td>
</tr>
<tr>
<td>Treatment Response</td>
<td>treatmnent response</td>
<td>categorical</td>
<td>CR, DP, PR, SurPR, VGPR</td>
</tr>
</tbody></table>

</br>
</p>

<a href="https://figshare.com/articles/dataset/_Clinical_characteristics_and_outcome_/178061" target="_blank" rel="noopener noreferrer">
Download the dataEV2013 dataset</a> &nbsp; &nbsp; &nbsp;
<a href="https://figshare.com/articles/dataset/_Clinical_characteristics_and_outcome_/178061" target="_blank" rel="noopener noreferrer">
<img src="download_button.png" align="centre" width="150">
</a>


</br>
</p>

<hr>

<!-- dataYBC2019 dataYBC2019 dataYBC2019 dataYBC2019 dataYBC2019 dataYBC2019 dataYBC2019 dataYBC2019 dataYBC2019 dataYBC2019      -->

<h3>dataYBC2019</h3>
Quantitative characteristics: 7 patients, 11 features, released in 2019.  License: CC BY-NC 4.0. File type: .xls
</br>
<a href="https://doi.org/10.1371/journal.pone.0225998" target="_blank" rel="noopener noreferrer">Original dataset article</a>.
</br>
</p>

<table class="table table-bordered table-hover table-condensed">
<thead><tr><th title="Field #1">feature</th>
<th title="Field #2">meaning</th>
<th title="Field #3">type</th>
<th title="Field #4">values</th>
</tr></thead>
<tbody><tr>
<td>Age at Dx.</td>
<td>Age of the patient at diagnosis</td>
<td>years</td>
<td>1.5, ..., 3.5</td>
</tr>
<tr>
<td>Age at relapse</td>
<td>Age of the patient at relapse</td>
<td>years</td>
<td>4.1, ..., 8.6</td>
</tr>
<tr>
<td>HDCT1 regimen</td>
<td>first high-dose chemotherapy</td>
<td>binary</td>
<td>TTC, CEC</td>
</tr>
<tr>
<td>HDCT2 regimen</td>
<td>second high-dose chemotherapy</td>
<td>binary</td>
<td>MEC, MIBG-TM</td>
</tr>
<tr>
<td>Interval to relapse</td>
<td>Interval (m) to relapse</td>
<td>months</td>
<td>12, ..., 75</td>
</tr>
<tr>
<td>MYCN status</td>
<td>amplified (A) or not amplified (NA)</td>
<td>binary</td>
<td>A, NA</td>
</tr>
<tr>
<td>Patient #</td>
<td>ID</td>
<td> </td>
<td>code</td>
</tr>
<tr>
<td>Relapsed sites</td>
<td>relapse sites in the body</td>
<td>categorical</td>
<td>Primary, Brain, bone, LNs, BM</td>
</tr>
<tr>
<td>Stage at Dx</td>
<td>only metastistic tumors</td>
<td>categorical</td>
<td>4</td>
</tr>
<tr>
<td>Treatment prior to haplo-SCT</td>
<td>treatment prior to haploidentical stem<br/>cell transplantation</td>
<td>categorical</td>
<td>Surgery, L-RT, CT×5, CT×6, CT×7</td>
</tr>
<tr>
<td>Tumor status at haplo-SCT</td>
<td>tumor status at athaploidentical stem<br/>cell transplantation</td>
<td>categorical</td>
<td>PR, CR, VGPR</td>
</tr>
</tbody></table>
</br>
</p>

<a href="https://figshare.com/articles/dataset/Patient_characteristics_/11367095" target="_blank" rel="noopener noreferrer">
Download the dataYBC2019 dataset</a> &nbsp; &nbsp; &nbsp;
<a href="https://figshare.com/articles/dataset/Patient_characteristics_/11367095" target="_blank" rel="noopener noreferrer">
<img src="download_button.png" align="centre" width="150">
</a>


</br>
</p>

<hr>

<h3>dataYM2018</h3>
Quantitative characteristics: 169 patients, 13 features, released in 2018. License: CC BY-NC 4.0. File type: .xls
</br>
<a href="https://doi.org/10.7717/peerj.5665" target="_blank" rel="noopener noreferrer">Original dataset article</a>.
</br>
</p>

<table class="table table-bordered table-hover table-condensed">
<thead><tr><th title="Field #1">feature</th>
<th title="Field #2">meaning</th>
<th title="Field #3">type</th>
<th title="Field #4">values</th>
</tr></thead>
<tbody><tr>
<td>age</td>
<td>&lt;12 months, 1, 12–60 months, 2, ≥60 months;</td>
<td>integer</td>
<td>0, 1, 2</td>
</tr>
<tr>
<td>autologous stem cell transplantation</td>
<td>Autologous stem cell transplantation: 0: no, 1: yes.</td>
<td>binary</td>
<td>0, 1</td>
</tr>
<tr>
<td>degree of differentiation</td>
<td>Degree of differentiation: 0: undifferentiated subtype;</td>
<td>categorical</td>
<td>0, 1, 2</td>
</tr>
<tr>
<td> </td>
<td>1: poorly differentiated subtype; 2: differentiating subtype;</td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>Histology </td>
<td>1: FH favorable histology, 0: UF unfavorable histology</td>
<td>binary</td>
<td>0, 1</td>
</tr>
<tr>
<td>MYCN status</td>
<td>Status of nMYC oncogene: 0, amplified, 1, unamplified;</td>
<td>binary</td>
<td>0, 1</td>
</tr>
<tr>
<td>outcome</td>
<td>Clinical Outcome: 1, dead of disease, 0, alive or lost follow-up;</td>
<td>binary</td>
<td>0, 1</td>
</tr>
<tr>
<td>radiation</td>
<td>Radiation: 0, no, 1, yes;</td>
<td>binary</td>
<td>0, 1</td>
</tr>
<tr>
<td>Risk</td>
<td>Risk group: 0: intermediate-risk; 1: high-risk.</td>
<td>categorical</td>
<td>0, 1</td>
</tr>
<tr>
<td>sex</td>
<td>0: male; 1: female</td>
<td>integer</td>
<td>0, 1</td>
</tr>
<tr>
<td>site</td>
<td>primary tumor Site: 0, adrenal gland, 1, mediastinum, 2, others.</td>
<td>categorical</td>
<td>0, 1, 2</td>
</tr>
<tr>
<td>stage</td>
<td>Stage of the tumor</td>
<td>categorical</td>
<td>1, 2, 3, 4</td>
</tr>
<tr>
<td>surgical methods</td>
<td>total or partial resection</td>
<td>binary</td>
<td>0, 1</td>
</tr>
<tr>
<td>time</td>
<td>overall survival</td>
<td>months</td>
<td>1, ..., 100</td>
</tr>
</tbody></table>
</br>
</p>


<a href="https://dfzljdn9uc3pi.cloudfront.net/2018/5665/1/RAW_5.xls " target="_blank" rel="noopener noreferrer">
Download the dataYM2018 dataset</a> &nbsp; &nbsp; &nbsp;
<a href="https://dfzljdn9uc3pi.cloudfront.net/2018/5665/1/RAW_5.xls " target="_blank" rel="noopener noreferrer">
<img src="download_button.png" align="centre" width="150">
</a>


</br>
</p>

<hr>




</body>
</html>
